Safety and Efficacy of BAY 94-9027, a Prolonged-Half-Life Factor VIII

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


    M T Reding, University of Minnesota Medical Center, Minneapolis, MN, USA., H J Ng, Department of Haematology, Singapore General Hospital, Singapore.,
  • Lone Hvitfeldt Poulsen
  • M E Eyster, Penn State Hershey Medical Center, Hershey, PA, USA., I Pabinger, Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria., H-J Shin, Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea., R Walsch, Bayer Vital GmbH, Leverkusen, Germany., M Lederman, Bayer, Whippany, NJ, USA., M Wang, Bayer, Whippany, NJ, USA., M Hardtke, Bayer Pharma AG, Drug Discovery, 13353 Berlin, Germany, L A Michaels, Bayer, Whippany, NJ, USA.
BACKGROUND: BAY 94-9027 is a B-domain-deleted prolonged-half-life recombinant factor VIII (FVIII) conjugates in a site-specific manner with polyethylene glycol. OBJECTIVE: Assess efficacy and safety of BAY 94-9027 for prophylaxis and treatment of bleeds in patients with severe hemophilia A PATIENTS/METHODS: In this multinational, phase 2/3, partially randomized, open-label trial, males aged 12-65 years with FVIII <1% and ≥150 exposure days to FVIII received BAY 94-9027 for 36 weeks on demand or prophylactically at intervals determined following a 10-week run-in period on 25 IU/kg body weight 2x/wk. Patients with >1 bleed during the run-in subsequently received 30-40 IU/kg 2x/wk; patients with ≤1 bleed were eligible for randomization to every-5-days (45-60 IU/kg) or every-7-days (60 IU/kg) prophylaxis (1:1) for 26 additional weeks until randomization arms were filled. Patients eligible but not randomized continued twice-weekly prophylaxis. Primary efficacy outcome was annualized bleeding rate (ABR). RESULTS: The intent-to-treat population included 132 patients (prophylaxis, n=112; on demand, n=20). Median ABR (quartile [Q1;Q3]) for patients treated 2x/wk not eligible for randomization (n=13) improved after dose increase (17.4 [14.3;26.0] to 4.1 [2.0;10.6]). Median ABR for patients randomized to every-5-days treatment (n=43) was 1.9 (0;4.2), similar to patients eligible for randomization but who continued treatment 2x/wk (n=11). Median ABR for 32/43 patients (74%) who continued every-7-days prophylaxis until study end was 0.96 (0.0;4.3). 636/702 bleeds (90.6%) were controlled with ≤2 infusions. No patient developed a FVIII inhibitor. CONCLUSIONS: BAY 94-9027 prevented bleeding across 3 individually tailored dose regimens and was effective for treatment of bleeds. This article is protected by copyright. All rights reserved.
TidsskriftJournal of Thrombosis and Haemostasis
Sider (fra-til)411-419
Antal sider9
StatusUdgivet - 22 feb. 2017


  • Clinical trial, Factor VIII, Hemophilia A, Prophylaxis, Recombinant Proteins

Se relationer på Aarhus Universitet Citationsformater

ID: 107967188